RecruitingNCT06323590
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot
Sponsor
University of Alabama at Birmingham
Enrollment
60 participants
Start Date
May 2, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria7
- Adult male or female, age ≥18
- Patients with newly diagnosed AML (de novo or secondary), treated with intensive induction chemotherapy (7+3+/-3rd agent). The 3rd agent will be midostaurin for FLT3-mutant AML or gemtuzumab ozogamicin for core-binding factor AML. Patients on clinical trial with an investigational agent added to 7+3, may be enrolled on the protocol after discussion between the investigators and medical monitors.
- Prior use of hypomethylating agents, lenalidomide, erythropoiesis stimulating agents and growth factors as allowed for treatment of myelodysplastic syndrome. Prior treatment for AML is not allowed.
- Cardiac function: Ejection fraction \>50-55%
- Adequate organ function for receipt for induction chemotherapy
- Patients with HIV and Hepatitis B or C should have controlled disease.
- Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment.
Exclusion Criteria7
- Any other active malignancy requiring treatment or with expected survival ≤1 year.
- Recipients of prior allogeneic stem cell transplant.
- Patients with psychiatric illness or social situation that would limit compliance with the study requirements.
- Patients with active CNS disease
- Patients with APL
- Received any investigational drugs within the 14 days prior to the first day of induction
- Pregnant and/or breastfeeding
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06323590
Related Trials
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT05554406216 locations
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146112 locations
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393175 locations
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649218 locations
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
NCT065142614 locations